CA
NZ
UK
AU
IND
US
According to In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx, it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. According to The company, safety was consistent …
Biohaven's license of BHV-1300 to Ono Pharma covering Japan, South Korea, Taiwan and ASEAN markets provides 80 million dollars in upfront cash plus a 20 million dollar near-term milestone, non-dilutiveCapitalthat extends the company's cash runway without requiring anEquityraise. Biohaven (NYSE:BHVN) retains rights to BHV-1300 …
According to In a release at 5:31 p.m. ET on October 7, 2026, Medtronic (NYSE:MDT), the final exchange ratio is 4.5939 MiniMed shares for each Medtronic ordinary share accepted. The offer expires at the end of October 9, 2026, at 12:00 midnight New York …
Neogen (NASDAQ:NEOG) released first quarter fiscal 2027 results for the quarter ended August 31, 2026 on October 6, 2026. Revenue of USD 222.8 million rose 6.5%, or 8.1% on a core basis. Domestic revenue was USD 110.1 million and international revenue was USD 112.7 …
Cooper Companies (NASDAQ:COO) traded at US$54.75 as of 8 October 2026, against an analyst consensus price target of US$69.57, an implied upside of approximately +27.1%.
DexCom, Inc. (NASDAQ:DXCM), a constituent of the S&P 500, traded at US$84.30 as of 8 October 2026, against an analyst consensus price target of US$90, an implied upside of approximately +6.8%.
Exelixis (NASDAQ:EXEL) traded at US$58.44 as of 8 October 2026, against an analyst consensus price target of US$50, an implied upside of approximately N/A.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a constituent of the Nasdaq-100, traded at US$224.41 as of 8 October 2026, against an analyst consensus price target of US$384, an implied upside of approximately +71.1%.
Amgen Inc. (NASDAQ:AMGN), a constituent of the Dow Jones Industrial Average, traded at US$413.08 as of 8 October 2026, against an analyst consensus price target of US$394.27, an implied upside of approximately -4.6%.
Ascendis Pharma (NASDAQ:ASND) traded at US$228.41 as of 8 October 2026, against an analyst consensus price target of US$315.61, an implied upside of approximately +38.2%.
Please wait processing your request...